FHLC
HealthcareFidelity MSCI Health Care Index ETF
Fidelity · Tracks MSCI USA IMI Health Care 25/50 Index · Inception Oct 21, 2013
Composite score
Based on a 0.084% expense ratio.
Based on $3.22B in net assets.
Top-10 holdings represent 50.6% of net assets.
Healthcare base · ETF wrapper · 1.32% TTM yield.
The composite is a weighted average of the four core sub-scores above (cost, tax efficiency, liquidity, concentration). Missing sub-scores fall back to the per-category median when the category has at least 50% data coverage, so funds without (e.g.) parsed N-PORT holdings aren't accidentally boosted by renormalization. Tracking quality is shown where computable but isn't currently part of the composite weighting. See methodology for formulas, the tracking-quality partial-coverage rationale, and the dimensions we deliberately don't score (methodology v0.5.1).
Use FHLC in our tools
Tool · Cost
Compare FHLC's fee against another fund
Compounds the 0.084% expense ratio against a peer over decades.
Tool · Overlap
Compare FHLC's holdings with peers
Pairwise holdings heatmap, pre-loaded with similar Healthcare funds.
Tool · TLH
Find a tax-loss harvesting partner for FHLC
Ranks every catalog fund by holdings overlap, flags wash-sale risk.
Tool · Placement
Where should this fund live across your accounts?
Asset-location optimizer — places each fund in taxable / tax-deferred / Roth.
Top holdings
| # | Holding | Weight |
|---|---|---|
| 1 | Eli Lilly & Co | 12.13% |
| 2 | Johnson & Johnson | 8.94% |
| 3 | AbbVie Inc | 6.03% |
| 4 | UnitedHealth Group Inc | 5.42% |
| 5 | Merck & Co Inc | 4.38% |
| 6 | Amgen Inc | 3.01% |
| 7 | Thermo Fisher Scientific Inc | 2.91% |
| 8 | Gilead Sciences Inc | 2.62% |
| 9 | Intuitive Surgical Inc | 2.62% |
| 10 | Abbott Laboratories | 2.55% |
Compare FHLC with another fund
Or skim the closest-overlap funds below.
Similar ETFs by holdings overlap
Open FHLC at a brokerage
Affiliate links — opening an account through these earns PlainIndex a one-time referral. Scoring is computed before any affiliate consideration; see our methodology and funding disclosure.